Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 10/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.67 |
| ▸ | CYP2B6 | P20813 | 5/20 | 0.67 |
| ▸ | CYP2E1 | P05181 | 4/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.60 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5208549 | 0.92 | CYP2A6 (0.63) | CYP2A6CYP3A4CYP2C19CYP2C9CYP2B6 | |
| SCHEMBL5201713 | 0.91 | CYP2A6 (0.62) | CYP2A6CYP3A4CYP2C19CYP2C9CYP2B6 | |
| SCHEMBL7067437 | 0.87 | CYP2A6 (0.65) | CYP2A6CYP3A4CYP2C19CYP2C9CYP2B6 | |
| SCHEMBL27697055 | 0.87 | CYP2A6 (0.69) | CYP2A6CYP3A4CYP2C19CYP2C9CYP2B6 | |
| SCHEMBL5718131 | 0.85 | PDE10A (0.49) | CYP2A6CYP3A4CYP2C19CYP2C9CYP2B6 | |
| SCHEMBL5717633 | 0.84 | CYP2C9 (0.44) | CYP2A6CYP3A4CYP2C19CYP2C9CYP2B6 | |
| SCHEMBL5493639 | 0.82 | CYP2A6 (0.70) | CYP2A6CYP3A4CYP2C19CYP2C9CYP2B6 | |
| SCHEMBL5017549 | 0.82 | CYP2A6 (0.70) | CYP2A6CYP3A4CYP2C19CYP2C9CYP2B6 | |
| SCHEMBL8204568 | 0.82 | CYP2A6 (0.80) | CYP2A6CYP3A4CYP2C19CYP2C9CYP2B6 | |
| SCHEMBL5017551 | 0.82 | CYP2A6 (0.70) | CYP2A6CYP3A4CYP2C19CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103391944-A | Novel macrolide intermediate and novel production process | MEIJI SEIKA PHARMA CO LTD | 2013-11-13 | — | — | CN | disclosed |
| EP-1363925-B8 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2007-04-25 | — | — | EP | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| CN-1492874-A | Macrolide antibiotics | — | 2004-04-28 | — | — | CN | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| US-20020151507-A1 | 9-oxime erythromycin derivatives | WU YONG-JIN (US) | 2002-10-17 | — | — | US | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
| US-20020025937-A1 | 9-OXIME ERYTHROMYCIN DERIVATIVES | PFIZER INC. | 2002-02-28 | — | — | US | disclosed |
| CN-1259135-A | 9-oxime erythromycin derivatives | PFIZER PROD INC (US) | 2000-07-05 | — | — | CN | disclosed |
| EP-0988308-A1 | 9-OXIME ERYTHROMYCIN DERIVATIVES | Pfizer Products Inc. (US) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998056800-A1 | 9-OXIME ERYTHROMYCIN DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | CYP2A6 522/4885CYP3A4 341/4885CYP2C19 209/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | CYP2A6 522/4885CYP3A4 341/4885CYP2C19 209/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | CYP2A6 562/4885CYP3A4 500/4885CYP2C19 380/4885 |
| US-20020025937-A1 | 9-OXIME ERYTHROMYCIN DERIVATIVES | CYP2C9, SULT1E1, CYP2D6 | CYP2A6 10/4885CYP3A4 37/4885CYP2C19 7/4885 |
| US-20020151507-A1 | 9-oxime erythromycin derivatives | CYP2C9, CYP2D6, SULT1E1 | CYP2A6 9/4885CYP3A4 38/4885CYP2C19 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.